Evidence map›Paper›PMID 36635391›Full record

Trial reportLeukemia2023

Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial.

Thilo Zander, Thomas Pabst, Sämi Schär, Stefan Aebi, Ulrich Mey, Urban Novak, Erika Lerch, Gaëlle Rhyner Agocs, Jeroen Goede, Zuzanna Maniecka and 4 more

Abstract readMulticenter StudyClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Leukemia, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Thilo ZanderDivision of Medical Oncology, Tumorzentrum, Luzerner Kantonsspital, Luzern, Switzerland. thilo.zander@luks.ch.ORCID 0000-0003-3691-7497
Thomas PabstDepartment of Medical Oncology, Inselspital, University of Bern, Bern, Switzerland.ORCID 0000-0002-6055-5257
Sämi SchärSwiss Group for Clinical Cancer Research (SAKK) Coordinating Center, Bern, Switzerland.ORCID 0000-0001-6108-4832
Stefan AebiDivision of Medical Oncology, Tumorzentrum, Luzerner Kantonsspital, Luzern, Switzerland.
Ulrich MeyOncology and Hematology, Kantonsspital Graubünden, Chur, Switzerland.
Urban NovakDepartment of Medical Oncology, Inselspital, University of Bern, Bern, Switzerland.
Erika LerchEOC-Istituto Oncologico della Svizzera Italiana, Ospedale San Giovanni, Bellinzona, Switzerland.
Gaëlle Rhyner AgocsDepartment of Medical Oncology, HFR Fribourg - Hôpital cantonal, Fribourg, Switzerland.
Jeroen GoedeKantonsspital Winterthur, Winterthur, Switzerland.
Zuzanna ManieckaSwiss Group for Clinical Cancer Research (SAKK) Coordinating Center, Bern, Switzerland.
Stefanie HayozSwiss Group for Clinical Cancer Research (SAKK) Coordinating Center, Bern, Switzerland.ORCID 0000-0002-2265-6559
Axel RüferDivision of Hematology, Tumorzentrum, Luzerner Kantonsspital, Luzern, Switzerland.
Christoph RennerOnkozentrum Hirslanden Zürich, Zürich, Switzerland.
Christoph DriessenDepartment of Medical Oncology and Hematology, Kantonsspital St. Gallen, St. Gallen, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Multiple MyelomaNeoplasms, Plasma CellAntineoplastic Combined Chemotherapy ProtocolsDexamethasoneHumansNeoplasm Recurrence, LocalThalidomideDexamethasonepomalidomideThalidomide

Identifiers

PMID36635391
PMCPMC9991905

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.